The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.
NEW YORK ( ETF Expert) -- Abbott Laboratories (ABT) sports five-year dividend growth of nearly 10% as well as a 3.5%+ annualized yield. Eli Lilly (LLY) has a P/E of 9, a 5.3% dividend yield and three-year earnings growth of 19%. Meanwhile, AstraZeneca (AZN) has a mammoth 35% trailing return on equity with a 5.8% annual dividend payout.
How in the world are investors overlooking the pharma space? Actually, the smart money hasn't overlooked it. The iShares DJ Pharmaceuticals Fund (IHE) is part of a select group of stock ETFs with a price above a 200-day moving average. In fact, not many stock ETFs in that select group can lay claim to year-to-date gains of about 8%.
There are four pharmaceutical ETFs for those intrigued by a value-driven uptrend. Each tends to capitalize on slightly different aspects of the drug universe. For example, SPDR S&P Pharma (XPH) maintains an equal weight strategy across 30 companies, which may lead to a greater focus on growth from the "anti Johnson & Johnsons." It follows that the yield is less compelling, but the potential for capital appreciation may be much greater. The aforementioned IHE is relatively similar to XPH; both are less yield-oriented than pharma stocks are known for. That said, IHE is 1/4 less volatile than the S&P 500 whereas XPH is only a "skosh" less volatile than the U.S. benchmark. In complete contrast, the Pharmaceutical HOLDRS (PPH) is dominated by Johnson & Jonhson (JNJ) with a 25% allocation. With only a handful of the largest brand name constituents moving PPH's needle -- Merck, Eli Lilly, Pfizer, etc. -- the yield is more compelling (approx 3%), but the growth prospects are less so. The PowerShares Dynamic Pharmaceuticals Fund (PJP) rounds out the field. Its tracking of a
Perhaps ironically, three of the Pharma ETF choices don't provide enough dividend yield, making the investor rely almost entirely on capital appreciation in bull market uptrends. The other, PPH, is so wrapped up in JNJ, one can't escape the company's decade-long underachievement. It follows that there may be a sweeter way to get your cake (yield) and eat it too (capital appreciation). Consider a fifth option -- the
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV